Asenjonamides A-C, antibacterial metabolites isolated from Streptomyces asenjonii strain KNN 42.f from an extreme-hyper arid Atacama Desert soil by Abdelkader, Mohamed S.A. et al.
 UWS Academic Portal
Asenjonamides A-C, antibacterial metabolites isolated from Streptomyces asenjonii
strain KNN 42.f from an extreme-hyper arid Atacama Desert soil
Abdelkader, Mohamed S.A.; Philippon, Thomas; Asenjo, Juan A.; Bull, Alan T.; Goodfellow,
Michael; Ebel, Rainer; Jaspars, Marcel; Rateb, Mostafa E.
Published in:
The Journal of Antibiotics
DOI:
10.1038/s41429-017-0012-0
E-pub ahead of print: 23/01/2018
Document Version
Peer reviewed version
Link to publication on the UWS Academic Portal
Citation for published version (APA):
Abdelkader, M. S. A., Philippon, T., Asenjo, J. A., Bull, A. T., Goodfellow, M., Ebel, R., ... Rateb, M. E. (2018).
Asenjonamides A-C, antibacterial metabolites isolated from Streptomyces asenjonii strain KNN 42.f from an
extreme-hyper arid Atacama Desert soil. The Journal of Antibiotics, 71, 425-431. https://doi.org/10.1038/s41429-
017-0012-0
General rights
Copyright and moral rights for the publications made accessible in the UWS Academic Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
Take down policy
If you believe that this document breaches copyright please contact pure@uws.ac.uk providing details, and we will remove access to the
work immediately and investigate your claim.
Download date: 17 Sep 2019
1 
 
Asenjonamides A–C, antibacterial metabolites isolated from Streptomyces 1 
asenjonii strain KNN 42.f from an extreme-hyper arid Atacama Desert soil 2 
Running head: Asenjonamides A-C from Streptomyces asenjonii  3 
Mohamed S. A. Abdelkader,1 Thomas Philippon,2 Juan A. Asenjo,3 Alan T. Bull,4 Michael 4 
Goodfellow,5 Rainer Ebel,2 Marcel Jaspars,2 and Mostafa E. Rateb6,7* 5 
  6 
1
 Department of Pharmacognosy, Faculty of Pharmacy, Sohag University, Sohag 82524, Egypt.  7 
2
 Marine Biodiscovery Centre, Department of Chemistry, University of Aberdeen, Aberdeen AB24 8 
3UE, UK. 9 
3
 Centre for Biotechnology and Bioengineering (CeBiB), Department of Chemical Engineering and 10 
Biotechnology, University of Chile, Beauchef, 851 Santiago, Chile. 11 
4
 School of Biosciences, University of Kent, Canterbury, Kent CT2 7NJ, UK. 12 
5
 School of Biology, Newcastle University, Ridley Building, Newcastle upon Tyne NE1 7RU, UK. 13 
6
 School of Science & Sport, University of the West of Scotland, Paisley PA1 2BE, UK.  14 
7
 Pharmacognosy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt.  15 
 16 
 17 
Correspondence: Mostafa E. Rateb (mostafa.rateb@uws.ac.uk; +441418483072)  18 
Key words: Asenjonamides A–C, antibacterial, β-diketone, spicamycins, Streptomyces 19 
asenjonii, Atacama Desert. 20 
 21 
 22 
2 
 
Bio-guided fractionation of the culture broth extract of Streptomyces asenjonii strain KNN 23 
42.f recovered from an extreme hyper-arid Atacama Desert soil in northern Chile led to the 24 
isolation of three new bioactive β-diketones; asenjonamides A–C (1-3) in addition to the 25 
known N-(2-(1H-indol-3-yl)-2-oxoethyl)acetamide (4), a series of bioactive acylated 4-26 
aminoheptosyl-β-N-glycosides; spicamycins A–E (5-9), and seven known diketopiperazines 27 
(10-16). All isolated compounds were characterized by HRESIMS and NMR analyses and 28 
tested for their antibacterial effect against a panel of bacteria.  29 
INTRODUCTION 30 
Natural products are considered a valuable resource for drug discovery due to their diverse 31 
chemical scaffolds which cannot be matched by any synthetic libraries. However, the 32 
discovery of new and bioactive natural products is quite challenging due to the high re-33 
isolation rate of known metabolites. One of the main strategies to address this problem is the 34 
isolation of new metabolites through the screening of novel microorganisms from neglected 35 
and underexplored habitats, particularly the extremobiosphere that includes desert biomes, 36 
the Antarctic, and the symbionts of insects.1-3 The incorporation of rigorous dereplication 37 
procedures into all stages of the natural product discovery process is a critical step to achieve 38 
this goal.  39 
One such neglected habitat is the Atacama Desert in northern Chile which is known for its 40 
extreme aridity. It has been arid over at least ∼15 million years and is considered to be the 41 
oldest and driest nonpolar desert on Earth.4 Some regions in the desert were described to 42 
feature “Mars-like” soils that were deemed too extreme for life to exist owing to extreme 43 
aridity, high levels of UV radiation, the presence of inorganic oxidants, areas of high salinity, 44 
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and very low concentrations of organic carbon.5 However, recent surveys indicated the 45 
presence of diverse culturable bacteria in the Atacama Desert.6,7 The successful 46 
incorporation of  taxonomic information into the drug discovery process 8 proved effective in 47 
the isolation of novel filamentous actinobacteria from the desert among which the novel anti-48 
HIV-1 lentzeosides A–F were discovered.9 Additionally, bio-guided and genome-guided 49 
screening of representatives of these actinobacteria led to the isolation of new bioactive 50 
metabolites belonging to diverse structural classes such as the antimicrobial chaxamycins10 51 
and chaxalactins11 from Streptomyces leeuwenhoekii C34T,12 the abenquines from 52 
Streptomyces sp. DB634,13 the antitumor atacamycins from Streptomyces leeuwenhoekii 53 
C38,14 and the cell invasion inhibitor chaxapeptin from S. leeuwenhoekii strain C58.15 More 54 
recently, co-cultivation of S. leeuwenhoekii with an Aspergillus isolate 55 
similarly led to the synthesis of new luteride and pseurotin derivatives.
16
   56 
As part of our ongoing program to investigate the Atacama extremobiosphere as a source of 57 
new bioactive natural products, we have focused our attention on Streptomyces asenjonii 58 
strain KNN 42.f which showed strong antibacterial effects and specific UV and 1H NMR 59 
pattern of secondary metabolites obtained from LCMS profile and associated NMR data. 60 
Bioactivity-guided screening of the strain led to the isolation of three new active metabolites 61 
belonging to the β-diketone family of polyketides in addition to thirteen known metabolites 62 
including the structurally unique antitumor antibiotic spicamycins, featuring different fatty 63 
acid residues, glycine, unusual amino sugars, and adenine units. Structure elucidation of 64 
these compounds was based on HRESIMS, 1D and 2D NMR analyses. The isolated 65 
compounds were screened for their antibacterial activity against a panel of bacteria.  66 
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RESULTS  67 
When screened against a panel of bacterial isolates, only Streptomyces asenjonii strain KNN 68 
42.f out of a collection of 10 different Atacama Desert-derived actinobacteria exhibited 69 
strong antibacterial effects against Gram positive and Gram negative target microorganisms. 70 
Bioactivity-guided fractionation of a large scale fermentation broth of this strain revealed the 71 
CH2Cl2 and EtOAc fractions to be the most active. Subjecting these fractions to multiple 72 
steps of medium and high pressure preparative C-18 chromatography resulted in the isolation 73 
of three new and thirteen known natural products based on HRESIMS and NMR data (Figure 74 
1).  75 
Compound (1) was obtained as a white amorphous powder. Its molecular formula 76 
C13H23NO3 was determined by analysis of its HRESIMS quasi-molecular ion peak at m/z 77 
264.1565 [M+Na]+, indicating three degrees of unsaturation. The analysis of 1H, 13C (Table 78 
1) and multiplicity-edited HSQC NMR spectra revealed the presence of one methyl triplet 79 
(δC/δH 13.6/0.88, C-9), one methyl doublet (δC/δH 14.2/1.12, C-11), one methyl singlet (δC/δH 80 
11.4/1.68, C-10), five methylenes of which one was oxygenated (δC/δH 59.5/3.36, C-2'), one 81 
aliphatic methine (δC/δH 47.0/4.08, C-2), one olefinic methine (δC/δH 142.6/6.79, C-5) and 82 
three quaternary carbons, two of which were assigned to an amide carbonyl (δC 170.7, C-1) 83 
and an α,β-unsaturated keto carbonyl (δC 197.4, C-3), respectively. The COSY spectrum 84 
revealed distinct spin systems, comprising the one of the olefinic H-5 through H3-9 85 
consistent with a hexenyl moiety, another one of the NH through H2-2' which indicated a 86 
hydroxyethylamino moiety in compound (1) (Figure 2). The HMBC correlations H3-11 to C-87 
1, C-2 and C-3 located this methyl doublet between 2 carbonyl moieties, while the 88 
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correlations of H3-10 to C-5, C-4 and C-3 connected the hexenyl moiety to the C-3 ketone 89 
(Figure 2). The HMBC correlations of NH and H2-1' to C-1 confirmed the attachment of the 90 
hydroxyethylamino moiety to the C-1 amide. NOESY correlations between H3-10 and H2-6 91 
established the E configuration for the double bond in the hexenyl moiety. The only 92 
compound close to our β-diketone was siphonarienedione which was reported naturally17 and 93 
through stereoselective total synthesis.18 Although the close similarity of siphonarienedione 94 
13CNMR data, coupling patterns and optical rotation data to (1), it could not be used to 95 
assign the stereochemistry as siphonarienedione has four additional stereocentres. Based on 96 
these findings, the structure of (1) was established as depicted, representing a new natural 97 
product for which we propose the name asenjonamide A. 98 
Compound (2) was obtained as a white amorphous powder, its molecular formula 99 
C11H19NO2
 
was derived from HRESIMS analysis of its quasi-molecular ion peak at m/z 100 
220.1304 [M+Na]+, consistent with three degrees of unsaturation. The 1H and 13C NMR 101 
spectral data of (2) (Table 1) in addition to the NOESY correlations were almost identical to 102 
those of 1, with the exception of the absence of resonances for the hydroxyethyl moiety 103 
which was supported by the molecular weight of (2) being 44 amu less than that of (1). This 104 
unambiguously led to the elucidation of the structure of (2) as shown in Figure 1 as a new 105 
natural product for which the name asenjonamide B is proposed.  106 
Compound (3) was obtained as a white amorphous powder, and its molecular formula was 107 
assigned as C11H17NO2
 
based on HRESIMS analysis of its quasi-molecular ion peak at m/z 108 
196.1330 [M+H]+ which indicated four degrees of unsaturation. The close similarity of this 109 
molecular formula to (2), with only 2 amu less and the absence of some proton resonances in 110 
the 1H NMR indicated the same chemical class with one extra ring in the structure of (3). 111 
6 
 
The COSY correlations of H2-6 through H3-9 confirmed the n-butyl side chain (Figure 2). 112 
The HMBC correlations of H3-11 to C-1, C-2 and C-3 and of H3-10 to C-3, C-4 and C-5 113 
established the 2-amino-2,4-dimethylcyclopent-4-ene-1,3-dione moiety. The HMBC 114 
correlations of H2-6 to C-1, C-5 and C-4 confirmed the connectivity of the aliphatic chain to 115 
C-5. Attempts to apply Mosher’s ester method failed and the compound decomposed. On 116 
that basis, compound (3) is considered a new natural product for which we propose the name 117 
asenjonamide C. 118 
Compound (4) was identified as N-(2-(1H-indol-3-yl)-2-oxoethyl)acetamide based on 119 
comparing its accurate mass and NMR spectra with literature data.19,20 Chemical screening 120 
of the EtOAc extract led to the isolation of a series of five acylated 4-aminoheptosyl-β-N-121 
glycosides, spicamycins A–E (5-9) featuring an adenine base, an unusual amino sugar, and 122 
aliphatic side chains of 8-12 CH2 groups ending in an isopropyl moiety. The structures of 123 
these compounds were elucidated by direct comparison of their HRESIMS and NMR 124 
spectroscopic data with literature data.19 Their HRESIMS analysis (see SI) showed a 125 
characteristic pattern with quasi-molecular ion peak at m/z 566.3320 [M+H]+ establishing the 126 
molecular formula C26H43N7O7 which was assigned for spicamycin A. Subsequent increases 127 
of 14 amu in the molecular ions corresponded to additional CH2 groups giving spicamycins 128 
B–E. This was supported by 1H NMR spectra which were virtually identical to those 129 
previously reported (See SI).21 Their structure was confirmed through the first total synthesis 130 
of one of the spicamycin congeners, SPM VIII.22 They were initially obtained as a non-131 
separable mixture of seven compounds from the culture broth of Streptomyces alanosinicus 132 
879-MT3 and reported as potent differentiation inducer of HL-60 human promyelocytic 133 
leukemia cells.21,23 134 
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Finally, the isolated diketopiperazine compounds were identified based on comparing their 135 
accurate mass, NMR, and optical rotation data with literature as cyclo(L-Pro-L-Val) (10),24 136 
cyclo(L-Pro-L-Phe) (11),24 cyclo(L-Pro-L-Tyr) (12),25 brevianamide F (13),26 cyclo(3-137 
hydroxy-L-Pro-L-Leu) (14),27 cyclo(3-hydroxy-L-Pro-L-Phe) (15),28 and cyclo(3-hydroxy-L-138 
Pro-L-Tyr) (16).29  139 
The preliminary bio-guided isolation revealed the CH2Cl2 and EtOAc fractions to possess 140 
antimicrobial effects (data not shown). Asenjonamides A–C (1-3), isolated from the CH2Cl2 141 
fractions, exhibited significant antibacterial effects against Gram-positive strains with 142 
asenjonamide C (3) showing activity comparable to that of the positive control tetracycline 143 
(Table 2). Additionally, (3) also exhibited strong activity against Gram-negative strains in 144 
relation to tetracycline and moderate effect against M. smegmatis. Moreover, spicamycins 145 
A–E (5-9) exhibited weak antibacterial effects against Gram-positive strains in the MIC 146 
range of 70-85 µg/mL but no effects against Gram-negative strains at the highest 147 
concentration used (100 µg/mL).  On the other hand, compound (5) and all diketopiperazine 148 
compounds (10-16) didn’t exhibit any antibacterial effects against all tested strains at the 149 
highest concentration used (100 µg/mL, data not shown).  150 
  151 
DISCUSSION 152 
The Atacama Desert is considered to be the oldest and driest nonpolar desert on Earth, being 153 
arid since the Jurassic period and developing to hyper-aridity during the Miocene period.6 154 
Initially, the hyper-arid core of the Atacama Desert was considered by some to be too 155 
extreme for microbial life to exist,4 but subsequent investigations led to the recovery of 156 
diverse cultivable microorganisms from this harsh environment indicating that it could 157 
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provide another unexpected resource of microbiological diversity. The discovery that a 158 
representative of a recently described Streptomyces species isolated from an extreme hyper-159 
arid Atacama Desert  soil synthesizes sixteen specialized metabolites that belong to different 160 
chemical classes underlines the premise that extreme environmental conditions give rise to a 161 
unique actinobacterial diversity which is the basis of novel chemistry.7 Indeed, to date, our 162 
taxonomic approach to the detection of new natural products from novel filamentous 163 
actinobacteria has led to the discovery of about 50 specialized metabolites representing 164 
diverse chemical classes , including alkaloids, peptides, polyketides, macrolides and terpenes 165 
that exhibit a range of biological activities.9-16 Most of these new compounds have been 166 
isolated from novel streptomycetes, notably ones, like S. asenjonii and S. leeuwenhoekii, that 167 
form deep rooted subclades in single and concatenated Streptomyces gene trees.15,30 Since 168 
our project began, numerous streptomycetes have been obtained from the 169 
complete range of hyper-arid and extreme hyper-arid habitats, six of which 170 
have been taxonomically characterized.
31 Such novel filamentous actinobacteria 171 
known to be present in the Atacama Desert landscape are a feature of an immense untapped 172 
resource for the search and discovery of the new generation of antibiotics needed for 173 
healthcare.7,20 174 
In the current study, strong antibacterial activity was the driving force for the selection of S. 175 
asenjonii isolate KNN 42.f. Chromatographic separation and spectroscopic identification of 176 
active CH2Cl2 fractions led to the identification of asenjonamides A–C, new members of β-177 
diketone subclass of polyketides which exhibited a broad antibacterial effect against a panel 178 
of different Gram-positive and Gram-negative bacteria with asenjonamide C showing a 179 
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comparable effect to that of the positive control, tetracycline. Based on inspection of their 180 
structures, the biosynthesis of these polyketides may be similar to that of the non-peptide 181 
part of calcaripeptide A32 isolated from Calcarisporium sp. strain KF525 or the anti-HIV 182 
inhibitor aetheramide A33 from Aetherobacter sp. strain SBSr003.  183 
Despite the revolutionary effects of environmental metagenomics on 184 
revealing microbial diversity, there remain powerful reasons for isolating 185 
and observing the behavior of organisms in culture. Recently, a 186 
spectacular diversity of actinobacteria has been detected and described in 187 
both low and very high altitude habitats of the Atacama region that 188 
include a putative new sub-order, and several new classes, families and 189 
numerous genera.
30
 The presence of such actinobacterial dark matter 190 
strongly supports the view that the extremobiosphere is a prime landscape 191 
for bioprospecting activities. However, while mining such metagenomic 192 
resources for novel natural products is a legitimate route for discovery, 193 
continued efforts to bring these rare and dark phylotypes into laboratory 194 
culture should not be neglected. Furthermore, culture-based studies also 195 
allow to carry out co-cultivation experiments, and we have successfully 196 
adopted this approach to include Atacama Desert microorganisms whereby 197 
many compounds were observed only in co-cultures of actinobacteria and 198 
fungi, but not in axenic cultures of the fungus or bacterium.
16,34
     199 
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Experimental 200 
General experimental procedures. Optical rotations were measured in methanol on a Perkin 201 
Elmer 241 instrument at the sodium D line (589 nm). 1H and 13C NMR spectra were 202 
recorded at 25 °C with a Varian VNMRS 600 MHz NMR spectrometer. High-resolution 203 
mass spectra were acquired with a Thermo Scientific LTQ/XL Orbitrap using the following 204 
parameters: analyzer: FTMS, mass range: normal full ms 100-2000, resolution: 30,000. For 205 
LC-ESIMS, gradient separation was achieved using a Sun Fire C-18 analytical HPLC 206 
column (5 µm, 4.6 × 150 mm, Waters) with a mobile phase of 0-100% MeOH over 30 min at 207 
a flow rate of 1 mL/min. HPLC was performed on Agilent 1260 Infinity preparative HPLC 208 
system with an Agilent Eclipse XDB-C18 column (5 µm, 10 × 250 mm, Agilent 209 
technologies, USA) monitored using an Agilent photodiode array detector. Detection was 210 
carried out at 220, 254, 280, 350, and 400 nm. MPLC separations were carried out on 211 
Biotage system using reversed-phase pre-packed columns. Detection was carried out at 220 212 
and 280 nm. Diaion HP-20 was obtained from Resindion S.R.L., a subsidiary of Mitsubishi 213 
Chemical Co., Binasco, Italy.  214 
Microorganism isolation and identification. Streptomyces asenjonii strain KNN 42.f was 215 
recovered from a plate of Gauze’s No.1 agar35 following inoculation with a suspension of an 216 
extreme hyper-arid soil collected by ATB in 2010 from the Yungay core region of the 217 
Atacama Desert (24°06’18.6”S,70°01’55.6”W at 1016 m asl).30 Phylogenetic analysis of 218 
KNN 42.f and other isolates recovered from the same region was performed through 16S 219 
rRNA gene sequencing and showed that these strains were belonging to new species within 220 
the genus Streptomyces, and KNN 42.f was identified as Streptomyces asenjonii KNN 42.f 221 
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and deposited in the NRRL public service collection under the accession number NRRL B-222 
65049.30   223 
Microbial fermentation, extraction and isolation. Streptomyces asenjonii strain KNN 42.f 224 
was fermented on modified ISP2 medium comprising malt extract (4.0 g), yeast extract (10.0 225 
g), dextrose (10.0 g), glycerol (10.0 g) and distilled water to 1 L, pH 7.0. It was grown at a 226 
volume of 4 L by shaking at 180 rpm in an incubator shaker at 30 °C for 7 days when HP-20 227 
resin beads were added, followed by shaking at 180 rpm for 6 h before harvest. The 228 
harvested fermentation broth was centrifuged at 3000 rpm for 20 min, and the HP20 was 229 
washed with distilled water and then extracted with methanol (4 × 200 mL). The successive 230 
MeOH extracts were combined and concentrated in vacuo yielding 2.3 g of residue. The 231 
latter was suspended in distilled water (300 mL) and then successively partitioned between 232 
n-hexane (300 mL × 3), CH2Cl2 (300 mL × 3) and EtOAc (300 mL × 3). Each fraction was 233 
concentrated under reduced pressure to give n-hexane extract (390 mg), CH2Cl2 extract (310 234 
mg), and EtOAc extract (260 mg), respectively. The CH2Cl2 fraction was subjected to flash 235 
chromatography on a Biotage system using a prepacked RP-18 column and a MeOH/H2O 236 
gradient to give 5 subtractions. Sub-fraction 1 was subjected to semi-preparative HPLC 237 
using MeCN–H2O (35–100% over 30 min, 100% for 5 min) at 2 mL/min flow rate affording 238 
compounds 10-16. Sub-fraction 2 afforded compounds 3 (1.3 mg) and 4 (2.1 mg), while sub-239 
fraction 3 afforded compounds 1 (1.0 mg) and 2 (5.9 mg) under the same HPLC conditions. 240 
The EtOAc fraction was subjected to flash chromatography on the Biotage system using 241 
prepacked RP-18 column chromatography using MeOH/H2O gradient to give 4 subtractions. 242 
Sub-fraction 2 was subjected to semi-preparative HPLC and a MeCN–H2O (15–100% over 243 
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30 min, 100% for 5 min) at a flow rate of 2 mL/min to afford compounds 5 (11 mg), 6 (3 244 
mg), 7 (7 mg), 8 (8 mg), and 9 (4.5 mg). 245 
Asenjonamide A (1). White amorphous powder; [α]20D +6.7 (c 0.1, MeOH); UV (MeOH) 246 
λmax (log ɛ) at 230 (3.8), 256 (2.5) nm; HRESIMS m/z [M+Na]+ 264.1565 indicating the 247 
molecular formula C13H19NO3 (calculated [M+Na]+ ion at m/z 264.1570); NMR data: see 248 
Table 1. 249 
Asenjonamide B (2). White amorphous powder; [α]20D +6.9 (c 0.12, MeOH); UV (MeOH) 250 
λmax (log ɛ) at 230 (3.7), 256 (2.6) nm; HRESIMS m/z [M+Na]+ 220.1304 indicating the 251 
molecular formula C11H17NO2 (calculated [M+Na]+ ion at m/z 220.1308); NMR data: see 252 
Table 1. 253 
Asenjonamide C (3). White amorphous powder; [α]20D +6.9 (c 0.15, MeOH); UV (MeOH) 254 
λmax (log ɛ) at 232 (3.6), 258 (2.7) nm; HRESIMS m/z [M+H]+ 196.1330 indicating the 255 
molecular formula C11H17NO2 (calculated [M+H]+ ion at m/z 196.1332); NMR data: see 256 
Table 1. 257 
Antibacterial screening. The antibacterial activity of all of the compounds was evaluated 258 
against Staphylococcus aureus ATCC 25923, Bacillus subtilis NCTC 2116, Escherichia coli 259 
ATCC 25922, Enterococcus faecalis ATCC 10541, and the acid fast strain Mycobacterium 260 
smegmatis ATCC607, using the agar diffusion method and regression line analysis.36 Filter 261 
paper disks containing amoxicillin (10 µg) and tetracycline (30 µg) were used as positive 262 
controls. Minimum inhibitory concentrations (MICs) against the panel of strains were 263 
calculated using the method described before albeit with minor modifications.37 In brief, 264 
tested strains were grown in Müller-Hinton (MH) broth to early stationary phase and then 265 
diluted to an OD600 = 0.005. The assays were performed in a 96-well microtiter plate format 266 
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in duplicate, with two independent cultures for each strain. All of the compounds were 267 
dissolved in DMSO (Sigma) and added to the cultures in wells to give a final concentration 268 
of DMSO of 10% that did not affect the growth of any of the tested strains. The effect of 269 
different dilutions of the compounds (up to 100 µg/mL) on growth was assessed after 18 h 270 
incubation at 37 °C using a Labsystems iEMS MF plate reader at OD620. The MIC value was 271 
determined as the lowest concentration showing no growth compared to the MH control. 272 
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Figure legends 375 
Figure 1. Structures of the compounds isolated from S. asenjonii strain KNN 42.f. 376 
Figure 2. Key COSY ( ), HMBC ( ) and NOESY ( ) correlations of 377 
compounds 1 and 3.  378 
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Figure 2. Key COSY ( ), HMBC ( ) and NOESY ( ) correlations of 386 
compounds 1 and 3.  387 
 388 
Table 1. 1H (600 MHz) and 13C (150 MHz) NMR spectroscopic data of 1-3 (298 K, DMSO-389 
d6). 390 
 1 2 3 
No. δC, mult.* δH (mult, J in Hz) δC, mult. δH (mult, J in Hz) δC, mult.* δH (mult, J in Hz) 
1 170.7, C - 172.6, C - 203.8, C - 
2 47.0, CH 4.09 (q) 47.0, CH 4.08 (q) 69.9, C - 
3 197.4, C - 197.6, C - 203.8, C - 
4 135.5, C - 135.6, C - 156.0, C - 
5 142.6, CH 6.76 (t, 7.1) 142.7, CH 6.78 t (7.1) 152.7, C - 
6 28.0, CH2 2.20 (q) 28.1, CH2 2.21 (q) 23.1, CH2 2.41 (t, 7.6) 
7 30.0, CH2 1.40 (m) 30.2, CH2 1.41 (m) 29.1, CH2 1.41 (m) 
8 21.9, CH2 1.30 (m)  21.8, CH2 1.32 (m)  22.1, CH2  1.29 (m) 
9 13.7, CH3 0.88 (t, 7.3) 13.8, CH3 0.89 (t, 7.3)  13.7, CH3 0.88 (t, 7.3) 
10 11.4, CH3 1.66 (s) 11.5, CH3 1.67 (s) 9.1, CH3 1.96 (s) 
11 14.2, CH3 1.12 (d, 7.0) 14.3, CH3 1.13 (d, 7.0) 20.0, CH3  1.14 (s) 
1' 41.2, CH2 3.08 (m) - - - - 
2'  59.5, CH2 3.36 (m)  - - - - 
NH2  - - 6.95 (bs) - 5.98 (bs) 
20 
 
NH  8.11 (bs) - - - - 
*
13C assignments were based on HSQC and HMBC spectra. 391 
 392 
 393 
 394 
 395 
 396 
Table 2. Antibacterial Activity of compounds 1-3 and 5-9. 397 
Compound 
Average MIC (µg/mL)a 
S. aureus B. subtilis E. coli E. faecalis  M. smegmatis 
1 3.6 3.9 16.8 12.2 18.6 
2 3.1 3.3 17.3 13.7 19.1 
3 1.8 1.7 5.4 3.9 10.3 
5 77.0 72.0 >100 >100 >100 
6 72.0 68.0 >100 >100 >100 
7 74.0 69.0 >100 >100 >100 
8 79.0 75.0 >100 >100 >100 
9 84.0 77.0 >100 >100 >100 
Tetracycline 1.5 1.2 4.1 2.9 3.8 
Amoxicillin 0.05 0.03 0.8 0.3 0.9 
a
 average of two independent replicates. 398 
 399 
 400 
 401 
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